Skip to content

Brought to you by

Dentons logo

Soapbox

A politics and policy blog

open menu close menu

Soapbox

  • Home
  • Who We Are
  • Topics
    • Topics
    • Federal Government Affairs
    • Dentons 50
    • State Attorneys General
    • Local Government Solutions
    • Elections
  • States
    • States
    • Colorado
    • Georgia
    • Hawai`i
    • Iowa
    • Pennsylvania
  • Guides and Resources
    • Guides and Resources
    • 2020 Presidential Election
    • Dentons Dialogue: US Policy Perspectives
    • State and Local
    • State Attorneys General
    • 100 Days Report 2021
    • US Policy Fall Preview 2021
  • Policy Scan 2021
    • Introduction
    • Administration
    • First 100 days
    • Policy in a Biden Administration
    • Congress
    • 50 state overview
    • Calendars

State Attorneys General and Unfair or Deceptive Acts or Practices (UDAP): What to expect in the wake of COVID-19

By Thurbert Baker, Bill McCollum, Daniel C. Gibb, Samuel Olens, and Jeff Modisett
June 17, 2020
  • State Attorneys General
Share on Facebook Share on Twitter Share via email Share on LinkedIn

Almost every state has its own deceptive and unfair trade practices law (UDAP), enforced by that state’s attorney general (AG). No fraud need be involved. The enforcement is civil, not criminal, but the statutory civil fines can be steep. The Federal Trade Commission (FTC) has ceded much of the enforcement to the states. In the wake of COVD-19, in addition to price-gouging, there will likely be many new enforcement actions against corporations who are alleged to have participated in unfair, deceptive or misleading acts that draw the attention of AGs. 

In some instances, these enforcement actions will involve multistate investigations in which sizeable numbers of attorneys general join together to investigate and possibly litigate. Some examples of areas that may face scrutiny include the following:

Health Care: Off-Label Drug Use

Off-label prescriptions, or the use of pharmaceutical drugs for an unapproved indication or in an unapproved dosage, dosage form or age group, is generally legal and frequently used by healthcare providers.

While in general there is nothing illegal in the off-label use of prescription drugs by doctors, marketing of pharmaceuticals or use of a drug for purposes outside of regulatory approvals is prohibited in most cases, and pharmaceutical companies have frequently been the subject of state AG investigations for doing so. As the race to find treatments for COVID-19 continues to accelerate, it is likely that representatives of some pharmaceutical companies will face scrutiny for promoting off-label use with hospitals and doctors.

Hotels and Leisure

Norwegian Cruise Lines is already being investigated under UDAP based on alleged communications from company employees to customers who prepaid for cruises, to the effect that the Norwegian Cruise Line ships had been sanitized, and so there was nothing to fear from COVID-19 in taking the planned cruise. The company allegedly had ample notice that its “sanitation” was insufficient to prevent the spread of the virus.

Advertising

Companies that host advertisements designed to sell products on their internet sites and take a fractional share of the sales revenue or profits garnered from the ads can be held responsible for misleading statements in the ads or misleading information about the charges to customers. This is true even in instances in which the seller/advertiser is located overseas and out of reach of a US enforcement action. Increased online sales suggest that these kinds of investigations are likely to increase. For example, with a huge surplus of used cars now on the market for the foreseeable future, AG investigations of false, misleading or deceptive advertising in online advertisements for used cars likely will increase, as well as investigations of misleading auto financing proposals – areas of traditional active UDAP enforcement.

Dentons’ State Attorney General practice is a full-service, nationwide practice to advise and assist clients when dealing with state AGs and their staff. If you have questions or an interest in more information on any of the items above and would like to discuss, please contact State AG practice co-chairs Thurbert Baker and Bill McCollum.

Related Information

Please also view Dentons’ recently published alert: “U.S. Food and Drug Administration, Federal Trade Commission Step-Up Enforcement of Product Misbranding and Efficacy Claims Related to COVID-19” for more insight on FDA and FTC actions related to COVID-19.

Share on Facebook Share on Twitter Share via email Share on LinkedIn
Subscribe and stay updated
Receive our latest blog posts by email.
Stay in Touch
COVID-19, Federal Trade Commission, Unfair or Deceptive Acts or Practices
Thurbert Baker

About Thurbert Baker

Attorney General Thurbert Baker co-leads Dentons' US State Attorney General practice and serves on the US Board. His practice focuses on corporate compliance and investigations, complex state legal and legislative matters, public policy and regulatory affairs, multi-state litigation, public sector procurements and regulatory matters.

All posts Full bio

Bill McCollum

About Bill McCollum

Former Florida Attorney General and Congressman Bill McCollum Co-Chairs Dentons' US State Attorney General Practice. His practice focuses on corporate compliance and investigations; complex state legal, regulatory and legislative matters; state anti-trust law enforcement; multi-state investigations and litigation; public policy; and advising and assisting companies with disruptive new technologies. He has represented and consulted for companies from a variety of industries with manufacturing and other business interests in Asia, Europe, the Middle East and Latin America.

All posts Full bio

Daniel C. Gibb

About Daniel C. Gibb

Dan is a member of Dentons' Public Policy practice and State Attorneys General group. In addition to advising business and commercial clients on legislative and public policy issues affecting their industries, he provides guidance to companies facing Federal Trade Commission (FTC) or state attorney general investigations. Dan also provides legal and strategic advice on a wide variety of consumer protection issues, including advertising law, unfair and deceptive trade practices and data privacy laws.

All posts Full bio

Samuel Olens

About Samuel Olens

Samuel S. Olens is a partner in Dentons' Public Policy practice and is a member of the firm's State Attorneys General group, based in the Atlanta office. His practice focuses on state attorneys general and local government affairs matters.

All posts Full bio

Jeff Modisett

Jeff Modisett

All posts

RELATED POSTS

  • State Attorneys General

Ohio Attorney General petitions for writ of mandamus to stop opioid trials

By Bill McCollum, Thurbert Baker, Samuel Olens, and Daniel C. Gibb
  • Dentons 50
  • State Attorneys General

Trump names picks for AG, CIA, National Security Advisor

By James Richardson
  • Dentons 50
  • State Attorneys General

CT AG leads states in support of feds’ CFPB

By James Richardson

About Dentons

Dentons is designed to be different. As the world’s largest law firm with 20,000 professionals in over 200 locations in more than 80 countries, we can help you grow, protect, operate and finance your business. Our polycentric and purpose-driven approach, together with our commitment to inclusion, diversity, equity and ESG, ensures we challenge the status quo to stay focused on what matters most to you. www.dentons.com

Dentons boilerplate image

Twitter

Categories

  • Federal Government Affairs
  • California
  • Dentons 50
  • Colorado
  • Georgia
  • Hawai`i
  • Iowa
  • Pennsylvania
  • State Attorneys General
  • Local Government Solutions
  • Elections
  • General

Subscribe and stay updated

Receive our latest blog posts by email.

Stay in Touch

Dentons logo white

© 2023 Dentons

  • Legal notices
  • Privacy policy
  • Terms of use
  • Cookies on this site